NO834780L - Preparat og fremgangsmaate for undersoekelse av fordoeyelsesfunksjoner - Google Patents

Preparat og fremgangsmaate for undersoekelse av fordoeyelsesfunksjoner

Info

Publication number: NO834780L
Authority: NO; Norway
Prior art keywords: tracer; units; binder; preparation according; preparation
Prior art date: 1982-04-23

Application number

NO834780A

Other languages

English (en)

Norwegian (no)

Inventor

Finn Norring Christensen

Jens Rasmus Jensen

Helle Bechgaard

Original Assignee

Benzon As Alfred

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-23

Filing date

1983-12-22

Publication date

1983-12-22

1983-12-22 Application filed by Benzon As Alfred filed Critical Benzon As Alfred

1983-12-22 Publication of NO834780L publication Critical patent/NO834780L/no

Links

238000002360 preparation method Methods 0.000 title claims description 117
238000000034 method Methods 0.000 title claims description 37
230000029087 digestion Effects 0.000 title 1
239000000700 radioactive tracer Substances 0.000 claims abstract description 175
239000011230 binding agent Substances 0.000 claims abstract description 123
238000000576 coating method Methods 0.000 claims abstract description 45
239000011248 coating agent Substances 0.000 claims abstract description 44
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 42
230000002496 gastric effect Effects 0.000 claims abstract description 37
210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 35
239000000126 substance Substances 0.000 claims abstract description 20
210000004877 mucosa Anatomy 0.000 claims abstract description 19
239000000203 mixture Substances 0.000 claims abstract description 18
238000009792 diffusion process Methods 0.000 claims abstract description 17
230000002829 reductive effect Effects 0.000 claims abstract description 17
230000006870 function Effects 0.000 claims abstract description 13
238000002372 labelling Methods 0.000 claims abstract description 9
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 27
239000012530 fluid Substances 0.000 claims description 21
210000002784 stomach Anatomy 0.000 claims description 20
230000027455 binding Effects 0.000 claims description 16
239000003456 ion exchange resin Substances 0.000 claims description 16
229920003303 ion-exchange polymer Polymers 0.000 claims description 16
239000000463 material Substances 0.000 claims description 14
238000005469 granulation Methods 0.000 claims description 13
230000003179 granulation Effects 0.000 claims description 13
230000005855 radiation Effects 0.000 claims description 13
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 12
239000012188 paraffin wax Substances 0.000 claims description 12
230000002285 radioactive effect Effects 0.000 claims description 11
230000001079 digestive effect Effects 0.000 claims description 10
238000006862 quantum yield reaction Methods 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 9
239000011573 trace mineral Substances 0.000 claims description 9
235000013619 trace mineral Nutrition 0.000 claims description 9
229920002678 cellulose Polymers 0.000 claims description 7
239000001913 cellulose Substances 0.000 claims description 7
235000010980 cellulose Nutrition 0.000 claims description 7
229920000642 polymer Polymers 0.000 claims description 7
239000011347 resin Substances 0.000 claims description 7
229920005989 resin Polymers 0.000 claims description 7
241000282414 Homo sapiens Species 0.000 claims description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
239000000084 colloidal system Substances 0.000 claims description 6
229920001577 copolymer Polymers 0.000 claims description 6
238000001514 detection method Methods 0.000 claims description 6
210000002249 digestive system Anatomy 0.000 claims description 6
238000009826 distribution Methods 0.000 claims description 6
239000001856 Ethyl cellulose Substances 0.000 claims description 5
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
239000002202 Polyethylene glycol Substances 0.000 claims description 5
239000000853 adhesive Substances 0.000 claims description 5
230000001070 adhesive effect Effects 0.000 claims description 5
235000019325 ethyl cellulose Nutrition 0.000 claims description 5
229920001249 ethyl cellulose Polymers 0.000 claims description 5
238000007654 immersion Methods 0.000 claims description 5
239000008108 microcrystalline cellulose Substances 0.000 claims description 5
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
235000019426 modified starch Nutrition 0.000 claims description 5
229920001223 polyethylene glycol Polymers 0.000 claims description 5
239000007787 solid Substances 0.000 claims description 5
241001465754 Metazoa Species 0.000 claims description 4
239000004793 Polystyrene Substances 0.000 claims description 4
BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims description 4
-1 diphosphonates Polymers 0.000 claims description 4
239000000945 filler Substances 0.000 claims description 4
125000000524 functional group Chemical group 0.000 claims description 4
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
229920002223 polystyrene Polymers 0.000 claims description 4
235000000346 sugar Nutrition 0.000 claims description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
229920002554 vinyl polymer Polymers 0.000 claims description 4
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 3
229920001817 Agar Polymers 0.000 claims description 3
108010010803 Gelatin Proteins 0.000 claims description 3
229920000881 Modified starch Polymers 0.000 claims description 3
229920002472 Starch Polymers 0.000 claims description 3
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 3
239000008272 agar Substances 0.000 claims description 3
235000010419 agar Nutrition 0.000 claims description 3
235000014633 carbohydrates Nutrition 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 3
239000012876 carrier material Substances 0.000 claims description 3
239000003729 cation exchange resin Substances 0.000 claims description 3
239000008273 gelatin Substances 0.000 claims description 3
229920000159 gelatin Polymers 0.000 claims description 3
235000019322 gelatine Nutrition 0.000 claims description 3
235000011852 gelatine desserts Nutrition 0.000 claims description 3
159000000014 iron salts Chemical class 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 3
229920000609 methyl cellulose Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
230000000704 physical effect Effects 0.000 claims description 3
239000004014 plasticizer Substances 0.000 claims description 3
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
239000008107 starch Substances 0.000 claims description 3
235000019698 starch Nutrition 0.000 claims description 3
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 3
235000014692 zinc oxide Nutrition 0.000 claims description 3
RNWHGQJWIACOKP-UHFFFAOYSA-N zinc;oxygen(2-) Chemical class [O-2].[Zn+2] RNWHGQJWIACOKP-UHFFFAOYSA-N 0.000 claims description 3
KPAPHODVWOVUJL-UHFFFAOYSA-N 1-benzofuran;1h-indene Chemical compound C1=CC=C2CC=CC2=C1.C1=CC=C2OC=CC2=C1 KPAPHODVWOVUJL-UHFFFAOYSA-N 0.000 claims description 2
VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 2
108010088751 Albumins Proteins 0.000 claims description 2
102000009027 Albumins Human genes 0.000 claims description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
239000005995 Aluminium silicate Substances 0.000 claims description 2
229920008347 Cellulose acetate propionate Polymers 0.000 claims description 2
DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 2
239000005977 Ethylene Substances 0.000 claims description 2
IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 2
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
239000005062 Polybutadiene Substances 0.000 claims description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
229930006000 Sucrose Natural products 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
229920006243 acrylic copolymer Polymers 0.000 claims description 2
235000012211 aluminium silicate Nutrition 0.000 claims description 2
125000000129 anionic group Chemical group 0.000 claims description 2
229920006320 anionic starch Polymers 0.000 claims description 2
230000000181 anti-adherent effect Effects 0.000 claims description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
239000008116 calcium stearate Substances 0.000 claims description 2
235000013539 calcium stearate Nutrition 0.000 claims description 2
125000002843 carboxylic acid group Chemical group 0.000 claims description 2
239000004359 castor oil Substances 0.000 claims description 2
235000019438 castor oil Nutrition 0.000 claims description 2
229920002301 cellulose acetate Polymers 0.000 claims description 2
229920001727 cellulose butyrate Polymers 0.000 claims description 2
229920006218 cellulose propionate Polymers 0.000 claims description 2
229920006037 cross link polymer Polymers 0.000 claims description 2
235000011180 diphosphates Nutrition 0.000 claims description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
239000001087 glyceryl triacetate Substances 0.000 claims description 2
235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
210000004347 intestinal mucosa Anatomy 0.000 claims description 2
150000002500 ions Chemical group 0.000 claims description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
239000008101 lactose Substances 0.000 claims description 2
229910000000 metal hydroxide Inorganic materials 0.000 claims description 2
150000004692 metal hydroxides Chemical class 0.000 claims description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
229960003330 pentetic acid Drugs 0.000 claims description 2
150000003904 phospholipids Chemical class 0.000 claims description 2
235000002949 phytic acid Nutrition 0.000 claims description 2
229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
229920002037 poly(vinyl butyral) polymer Polymers 0.000 claims description 2
229920000058 polyacrylate Polymers 0.000 claims description 2
229920000768 polyamine Polymers 0.000 claims description 2
229920002857 polybutadiene Polymers 0.000 claims description 2
239000004417 polycarbonate Substances 0.000 claims description 2
229920000515 polycarbonate Polymers 0.000 claims description 2
229920000728 polyester Polymers 0.000 claims description 2
239000004926 polymethyl methacrylate Substances 0.000 claims description 2
229920002689 polyvinyl acetate Polymers 0.000 claims description 2
239000011118 polyvinyl acetate Substances 0.000 claims description 2
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
235000008164 pyridoxal Nutrition 0.000 claims description 2
125000002050 pyridoxal group Chemical group 0.000 claims description 2
125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
229940081623 rose bengal Drugs 0.000 claims description 2
229930187593 rose bengal Natural products 0.000 claims description 2
STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims description 2
150000005619 secondary aliphatic amines Chemical class 0.000 claims description 2
210000002966 serum Anatomy 0.000 claims description 2
150000004760 silicates Chemical class 0.000 claims description 2
239000005720 sucrose Substances 0.000 claims description 2
150000008163 sugars Chemical class 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
229920001059 synthetic polymer Polymers 0.000 claims description 2
239000000454 talc Substances 0.000 claims description 2
229910052623 talc Inorganic materials 0.000 claims description 2
235000012222 talc Nutrition 0.000 claims description 2
150000003510 tertiary aliphatic amines Chemical class 0.000 claims description 2
229960002622 triacetin Drugs 0.000 claims description 2
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 2
229940070710 valerate Drugs 0.000 claims description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
239000001993 wax Substances 0.000 claims description 2
IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 claims 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims 1
229910052738 indium Inorganic materials 0.000 claims 1
230000035515 penetration Effects 0.000 claims 1
229960001124 trientine Drugs 0.000 claims 1
230000030136 gastric emptying Effects 0.000 abstract description 17
238000002386 leaching Methods 0.000 abstract description 14
235000013305 food Nutrition 0.000 abstract description 3
238000009472 formulation Methods 0.000 abstract description 3
210000005095 gastrointestinal system Anatomy 0.000 abstract description 2
238000005342 ion exchange Methods 0.000 abstract 1
239000008188 pellet Substances 0.000 description 54
230000000694 effects Effects 0.000 description 24
230000008901 benefit Effects 0.000 description 17
239000002245 particle Substances 0.000 description 14
239000007788 liquid Substances 0.000 description 13
238000013461 design Methods 0.000 description 12
238000012360 testing method Methods 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
238000000338 in vitro Methods 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
230000006399 behavior Effects 0.000 description 7
238000003745 diagnosis Methods 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
229920001429 chelating resin Polymers 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
238000002575 gastroscopy Methods 0.000 description 6
230000000968 intestinal effect Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 5
210000001198 duodenum Anatomy 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
235000021055 solid food Nutrition 0.000 description 5
230000003872 anastomosis Effects 0.000 description 4
239000002872 contrast media Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
238000011835 investigation Methods 0.000 description 4
230000007794 irritation Effects 0.000 description 4
210000000813 small intestine Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
231100000397 ulcer Toxicity 0.000 description 4
208000025865 Ulcer Diseases 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
238000002791 soaking Methods 0.000 description 3
210000001685 thyroid gland Anatomy 0.000 description 3
208000008279 Dumping Syndrome Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
208000032395 Post gastric surgery syndrome Diseases 0.000 description 2
239000004902 Softening Agent Substances 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
235000015278 beef Nutrition 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
229940039231 contrast media Drugs 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
238000000227 grinding Methods 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000000941 radioactive substance Substances 0.000 description 2
210000001599 sigmoid colon Anatomy 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000007217 Esophageal Stenosis Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
206010030194 Oesophageal stenosis Diseases 0.000 description 1
206010030201 Oesophageal ulcer Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
201000000660 Pyloric Stenosis Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
210000001815 ascending colon Anatomy 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
150000001555 benzenes Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000006229 carbon black Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910000423 chromium oxide Inorganic materials 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000001731 descending colon Anatomy 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
208000028299 esophageal disease Diseases 0.000 description 1
208000019064 esophageal ulcer Diseases 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
239000004744 fabric Substances 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
238000007455 ileostomy Methods 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000003871 intestinal function Effects 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
150000002497 iodine compounds Chemical class 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
229960004592 isopropanol Drugs 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
238000009206 nuclear medicine Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001711 oxyntic cell Anatomy 0.000 description 1
239000008016 pharmaceutical coating Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
235000012015 potatoes Nutrition 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
235000013599 spices Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000018556 stomach disease Diseases 0.000 description 1
239000000758 substrate Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
210000003384 transverse colon Anatomy 0.000 description 1
206010044697 tropical sprue Diseases 0.000 description 1
239000007966 viscous suspension Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1255—Granulates, agglomerates, microspheres
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Optics & Photonics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Dispersion Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Farming Of Fish And Shellfish (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Investigating Or Analysing Biological Materials (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Curing Cements, Concrete, And Artificial Stone (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Testing, Inspecting, Measuring Of Stereoscopic Televisions And Televisions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

NO834780A 1982-04-23 1983-12-22 Preparat og fremgangsmaate for undersoekelse av fordoeyelsesfunksjoner NO834780L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK183982		1982-04-23

Publications (1)

Publication Number	Publication Date
NO834780L true NO834780L (no)	1983-12-22

Family

ID=8108447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO834780A NO834780L (no)	1982-04-23	1983-12-22	Preparat og fremgangsmaate for undersoekelse av fordoeyelsesfunksjoner

Country Status (12)

Country	Link
US (1)	US4657755A (de)
EP (1)	EP0092993B1 (de)
JP (1)	JPS59500614A (de)
AT (1)	ATE40949T1 (de)
CA (1)	CA1222947A (de)
DE (2)	DE3379256D1 (de)
DK (1)	DK157733C (de)
FI (1)	FI834776A7 (de)
NO (1)	NO834780L (de)
NZ (1)	NZ204009A (de)
WO (1)	WO1983003762A1 (de)
ZA (1)	ZA832904B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5165410A (en) *	1987-05-15	1992-11-24	Medical & Scientific Enterprises, Inc.	Position indicating system for a multidiagnostic scanner
US5261406A (en) *	1991-01-15	1993-11-16	Medasys Inc.	Whole body imaging system
US5342609A (en) *	1991-10-22	1994-08-30	Mallinckrodt Medical, Inc.	Microfluidization of calcium/oxyanion-containing particles
US5344640A (en) *	1991-10-22	1994-09-06	Mallinckrodt Medical, Inc.	Preparation of apatite particles for medical diagnostic imaging
US5407659A (en) *	1991-10-22	1995-04-18	Mallinckrodt Medical, Inc.	Treated calcium/oxyanion-containing particles for medical diagnostic imaging
US5350584A (en) *	1992-06-26	1994-09-27	Merck & Co., Inc.	Spheronization process using charged resins
US5520904A (en) *	1995-01-27	1996-05-28	Mallinckrodt Medical, Inc.	Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
US5827497A (en) *	1996-08-14	1998-10-27	Mayo Foundation For Medical Education And Research	Charcoal-radionuclide agents for measurement of gastrointestinal transit
US20060073202A1 (en) *	2004-10-05	2006-04-06	Rocca Jose G	Dual component medicament delivery system
CN101516408A (zh) *	2006-07-19	2009-08-26	史密丝克莱恩比彻姆公司	放射性标记用于γ闪烁照相术评估的制剂的方法
US10299745B2 (en)	2014-12-29	2019-05-28	Loyola University Of Chicago	Traceable devices for gastrointestinal use and methods of use and manufacturing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2611730A (en) *	1950-09-02	1952-09-23	Simth Kline & French Lab	Medical preparation for reducing the body level of sodium
DK106457C (da) *	1962-01-23	1967-02-06	Ernst Helmer Hagstam	Røntgenkontrastmiddel med lille massefylde og fremgangsmåde til dets fremstilling.
NL7017227A (de) *	1969-12-27	1971-06-29
US4115540A (en) *	1976-06-16	1978-09-19	The University Of Kentucky Research Foundation	Radiodiagnostic agent
US4107283A (en) *	1976-07-19	1978-08-15	New England Nuclear Corporation	Tracer for circulation determinations
GB1576376A (en) *	1977-03-30	1980-10-08	Benzon As Alfred	Multiple-unit drug dose
US4243652A (en) *	1978-07-14	1981-01-06	The Procter & Gamble Company	Gastrointestinal scanning agent
GB2057420B (en) *	1979-08-30	1984-05-10	Standard Telephones Cables Ltd	Controlled release glass

1983
- 1983-04-22 DE DE8383302304T patent/DE3379256D1/de not_active Expired
- 1983-04-22 WO PCT/DK1983/000047 patent/WO1983003762A1/en not_active Ceased
- 1983-04-22 AT AT83302304T patent/ATE40949T1/de not_active IP Right Cessation
- 1983-04-22 CA CA000426523A patent/CA1222947A/en not_active Expired
- 1983-04-22 JP JP58501422A patent/JPS59500614A/ja active Granted
- 1983-04-22 DE DE198383302304T patent/DE92993T1/de active Pending
- 1983-04-22 EP EP83302304A patent/EP0092993B1/de not_active Expired
- 1983-04-22 US US06/568,184 patent/US4657755A/en not_active Expired - Fee Related
- 1983-04-25 ZA ZA832904A patent/ZA832904B/xx unknown
- 1983-04-26 NZ NZ204009A patent/NZ204009A/en unknown
- 1983-12-22 NO NO834780A patent/NO834780L/no unknown
- 1983-12-22 DK DK593083A patent/DK157733C/da not_active IP Right Cessation
- 1983-12-23 FI FI834776A patent/FI834776A7/fi not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0092993A3 (en)	1984-07-18
FI834776A0 (fi)	1983-12-23
WO1983003762A1 (en)	1983-11-10
DK157733C (da)	1990-07-16
CA1222947A (en)	1987-06-16
NZ204009A (en)	1986-03-14
EP0092993A2 (de)	1983-11-02
ZA832904B (en)	1984-01-25
DE3379256D1 (en)	1989-04-06
EP0092993B1 (de)	1989-03-01
DE92993T1 (de)	1984-03-29
JPS59500614A (ja)	1984-04-12
US4657755A (en)	1987-04-14
DK157733B (da)	1990-02-12
JPS6222971B2 (de)	1987-05-20
DK593083A (da)	1983-12-22
DK593083D0 (da)	1983-12-22
ATE40949T1 (de)	1989-03-15
FI834776A7 (fi)	1983-12-23

Publication	Publication Date	Title
Hardy et al.	1987	Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease
Fisher et al.	1982	Abnormal gallbladder emptying in patients with gallstones
Ibekwe et al.	2008	Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems
Brunner et al.	2003	Gastrointestinal transit and 5‐ASA release from a new mesalazine extended‐release formulation
Misiewicz et al.	1969	Effect of oral prostaglandin E1 on intestinal transit in man
Ashford et al.	1993	An in vivo investigation into the suitability of pH dependent polymers for colonic targeting
Wilson et al.	1988	Assessment of disintegration and dissolution of dosage forms in vivo using gamma scintigraphy
Fell et al.	1984	Imaging and behaviour of solid oral dosage forms in vivo
Hardy et al.	1993	Localization of drug release sites from an oral sustained‐release formulation of 5‐ASA (Pentasa®) in the gastrointestinal tract using gamma scintigraphy
NO834780L (no)	1983-12-22	Preparat og fremgangsmaate for undersoekelse av fordoeyelsesfunksjoner
Goto et al.	2004	Pharmaceutical design of a novel colon-targeted delivery system using two-layer-coated tablets of three different pharmaceutical formulations, supported by clinical evidence in humans
Scarpignato	1990	Gastric emptying measurement in man
Kamm	1992	The small intestine and colon: scintigraphic quantitation of motility in health and disease
Healey	1990	Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease
Larouche et al.	1995	Release of 5‐ASA from Pentasa in patients with Crohn's disease of the small intestine
Marvola et al.	2004	Neutron activation-based gamma scintigraphy in pharmacoscintigraphic evaluation of an Egalet® constant-release drug delivery system
Perkins et al.	1996	Nuclear medicine techniques in the evaluation of pharmaceutical formulations
Sutton et al.	2002	Quantitative detection of atropine‐delayed gastric emptying in the horse by the 13C‐octanoic acid breath test
Alpsten et al.	1982	Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated micro-granules
Hedenbro et al.	1988	Lack of correlation between fecal blood loss and drug-induced gastric mucosal lesions
AU1513283A (en)	1983-11-21	Composition and method for investigating alimentary functions
Tjen	1979	Cholescintigraphy
Blok et al.	1991	Scintigraphic investigation of the gastric emptying of 3 mm pellets in human volunteers
RU2536105C1 (ru)	2014-12-20	Способ одновременной оценки (диагностики) функции билиодигестивных и гастроэнтероанастомозов у больных, перенесших радикальные и паллиативные вмешательства по поводу рака головки поджелудочной железы
Khosla	1987	Gastrointestinal transit of dosage forms